STAT Examines 7 Questions Surrounding COVID-19 Vaccine Rollout; News Outlets Discuss Vaccine Research, Intellectual Property Issues

STAT: 7 looming questions about the rollout of a Covid-19 vaccine
“…The design, testing, and mass production of multiple vaccines has never been attempted on this type of timeline, making this moment a turning point in the development of vaccines to respond to new disease threats. But the complexity of that work may pale in comparison to what comes next — the rollout of hundreds of millions of doses of never-before-used vaccines across the United States and, eventually, around the world. … Some of the looming problems aren’t foreseeable. But here are some potential hurdles that might complicate this very important effort…” (Branswell/Silverman, 10/9).

Financial Times: AstraZeneca vaccine document shows limit of no-profit pledge (Mancini, 10/7).

The Hill: AstraZeneca’s no-profit pledge for vaccine has expiration date: report (Williams, 10/8).

Nature: What China’s speedy COVID vaccine deployment means for the pandemic (Cyranoski, 10/8).

STAT: Moderna vows not to enforce Covid-19 patents, but advocates say IP should be given to WHO (Silverman, 10/8).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.